Abstract 2481: Anti-Inflammatory Effect of Abciximab-Coated Stents In A Porcine Coronary Restenosis Model
Background: There is an increasing evidence to suggest that inflammation plays a pivotal role linking early vascular injury to the eventual consequence of neointimal growth and lumen compromise. The widespread use of drug-eluting stents has fundamentally altered the vascular response to injury by causing a more intense and prolonged inflammatory state. The aim of this study was to examine the anti-inflammatory effects of abciximab-coated stent in a porcine coronary overstretch restenosis model.
Methods: Ten abciximab-coated stents, ten sirolimus-eluting stents (SES), and ten paclitaxel-eluting stents (PES) were deployed with oversizing (stent/artery ratio 1.3:1) in porcine coronary arteries, and histopathologic analysis was assessed and correlated with neointimal formation at 28 days after stenting.
Results: At 28 days, the lumen area was 17.9±4.1, 17.5±5.1, and 18.9±7.5 mm2, and neointima area was 1.9±0.8, 2.2±1.1, and 2.8±1.6 mm2, and percent area stenosis was 9.6±5.0, 11.2±6.0, and 12.9±8.6% in abciximab-coated stent, SES, and PES group, respectively (p=NS). In neointima, most inflammatory cells were lymphohistiocytes. Significant positive correlations were found between the extent of inflammatory reaction and the neointimal area (r=0.55, p<0.001) and percent area stenosis (r=0.62, p<0.001). The number of inflammatory cells in neointima was 90.6±33.1/mm3, 102.5±43.2/mm3, and 190.2±56.9/mm3 in abciximab-coated stent, SES, and PES group, respectively (p=0.476 in abciximab vs. SES, p=0.049 in abciximab vs PES, p=0.087 in SES vs. PES, respectively).
Conclusion: Abciximab-coated stent showed inhibition of inflammatory cell infiltration and neointimal hyperplasia in a porcine coronary restenosis model.